Sam Brusco, Associate Editor12.07.21
Tech-enabled medtech product development services firm Veranex has acquired Worrell, expanding the company’s offerings and geographic reach. Veranex is the product of six complementary acquisitions backed by Summit partners, including Ximedica, Quartesian, Boston Healthcare Associates, Experien Group, IMM Recherche, and now Worrell.
“The addition of Worrell strengthens Veranex’s offerings as the leading global provider in the medical device and biotech space,” Veranex Executive Chairman Patrick Donnelly told the press. “By enhancing our human-centered design capabilities with a focus on Phase 0 strategy, design conceptualization, and human factors services, we complement our existing ISO-certified Phase 1-4 engineering and pilot-scale manufacturing capabilities.”
“We’re thrilled to welcome the employees of Worrell to Veranex,” added CEO David Dockhorn. “Kai Worrell joins Veranex as president of our product development and engineering business unit, with locations in Minneapolis, Providence, the San Francisco Bay Area, London, and Shanghai.”
“Worrell’s integration into Veranex comes at a perfect moment,” added Kai Worrell. “As medical device and biotech leaders around the world fuel their R&D pipelines, they need world class partners now more than ever. Adding Worrell’s 46 years of design expertise to the Veranex industry powerhouse will create new opportunities for improving global health outcomes.”
The transaction’s financial terms were not disclosed.
Veranex has offices on four continents, with staff including designers, engineers, market access, regulatory, quality, and clinical experts. Their full scope medtech development services include product design and engineering, evaluation services, clinical development, data management and analytics, regulatory affairs and quality management, and commercial strategy and market access.
The company touts experience in cardiovascular disease, women’s health, oncology, and ophthalmology.
“The addition of Worrell strengthens Veranex’s offerings as the leading global provider in the medical device and biotech space,” Veranex Executive Chairman Patrick Donnelly told the press. “By enhancing our human-centered design capabilities with a focus on Phase 0 strategy, design conceptualization, and human factors services, we complement our existing ISO-certified Phase 1-4 engineering and pilot-scale manufacturing capabilities.”
“We’re thrilled to welcome the employees of Worrell to Veranex,” added CEO David Dockhorn. “Kai Worrell joins Veranex as president of our product development and engineering business unit, with locations in Minneapolis, Providence, the San Francisco Bay Area, London, and Shanghai.”
“Worrell’s integration into Veranex comes at a perfect moment,” added Kai Worrell. “As medical device and biotech leaders around the world fuel their R&D pipelines, they need world class partners now more than ever. Adding Worrell’s 46 years of design expertise to the Veranex industry powerhouse will create new opportunities for improving global health outcomes.”
The transaction’s financial terms were not disclosed.
Veranex has offices on four continents, with staff including designers, engineers, market access, regulatory, quality, and clinical experts. Their full scope medtech development services include product design and engineering, evaluation services, clinical development, data management and analytics, regulatory affairs and quality management, and commercial strategy and market access.
The company touts experience in cardiovascular disease, women’s health, oncology, and ophthalmology.
